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ABSTRACT We assessed safety and tolerability of treatment with pirfenidone (1602–2403 mg·day−1) and
nintedanib (200–300 mg·day−1) in patients with idiopathic pulmonary fibrosis (IPF).
This 24-week, single-arm, open-label, phase IV study (ClinicalTrials.gov identifier NCT02598193)
enrolled patients with IPF with forced vital capacity % pred ⩾50% and diffusing capacity of the lung for
carbon monoxide % pred ⩾30%. Before initiating nintedanib, patients had received pirfenidone for
⩾16 weeks and tolerated a stable dose of ⩾1602 mg·day−1 for ⩾28 days. The primary end-point was the
proportion of patients who completed 24 weeks of combination treatment on pirfenidone (1602–
2403 mg·day−1) and nintedanib (200–300 mg·day−1). Investigators recorded treatment-emergent adverse
events (TEAEs), attributing them to pirfenidone, nintedanib, both or neither.
89 patients were enrolled; 73 completed 24 weeks of treatment (69 meeting the primary end-point) and
16 discontinued treatment prematurely (13 due to TEAEs). 74 patients had 418 treatment-related TEAEs,
of which diarrhoea, nausea and vomiting were the most common. Two patients had serious treatment-
related TEAEs.
Combined pirfenidone and nintedanib use for 24 weeks was tolerated by the majority of patients with
IPF and associated with a similar pattern of TEAEs expected for either treatment alone. These results
encourage further study of combination treatment with pirfenidone and nintedanib in patients with IPF.
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Introduction
Idiopathic pulmonary fibrosis (IPF) is a progressive, irreversible, fatal, fibrosing lung disease of unknown
cause [1, 2], with a survival rate lower than that reported for many common cancer types [1, 3–5].
Pirfenidone and nintedanib are approved as monotherapies for treatment of IPF [6, 7], and both received a
conditional recommendation for use in the 2015 update to the American Thoracic Society (ATS)/European
Respiratory Society (ERS)/Japanese Respiratory Society (JRS)/Latin American Thoracic Association (ALAT)
clinical practice guideline [8]. Although pirfenidone and nintedanib have both demonstrated efficacy in
reducing rates of disease progression compared with placebo, the disease is neither stopped nor reversed
and patients continue to experience lung function decline while on treatment [9–11].
The differing putative mechanisms of action of pirfenidone and nintedanib [12–14] provide a physiological
rationale for combining these two agents in an attempt to further reduce lung function decline in patients
with IPF [15]. Even though both agents target the fibrotic cascade, decreasing fibroblast and myofibroblast
production, and accumulation of extracellular matrix [12–14, 16, 17], evidence suggests that they may
target distinct aspects of the fibrotic cascade. Although its mechanism of action has not been fully
established, pirfenidone has been shown to act on multiple targets in vitro, including transforming growth
factor-β-triggered events, mediated through glioma-associated oncogene homolog 2 [12, 13]. Nintedanib is
a tyrosine kinase inhibitor that blocks intracellular signalling of platelet-derived growth factor receptors,
fibroblast growth factor receptors and vascular endothelial growth factor receptor [14].
Pirfenidone and nintedanib are both associated with gastrointestinal adverse events (AEs), with
pirfenidone mainly associated with nausea and nintedanib mainly associated with diarrhoea [9, 10, 18]. A
small Japanese randomised, double-blind, phase II dose-escalation trial of nintedanib (100–300 mg·day−1)
added to ongoing pirfenidone treatment (⩽1800 mg·day−1) for ⩽28 days, and its 1-year, open-label
extension, indicated that safety and tolerability of combination treatment in patients with IPF was in line
with AE profiles for each drug alone [19, 20]. Similarly, the recent INJOURNEY trial, an open-label,
randomised trial of pirfenidone (⩽2403 mg·day−1) added to nintedanib treatment (⩽300 mg·day−1) for
12 weeks, also found that the safety and tolerability profile of combination treatment was comparable with
that of the individual drugs [21]. However, there are limited data on long-term safety of combination
treatment. Here, we report results from a 24-week study investigating safety and tolerability of adding
nintedanib to stable pirfenidone treatment in patients with IPF.
Methods
Patients
Eligible patients were aged 40–80 years at start of screening, with IPF based on the ATS/ERS/JRS/ALAT
2011 guideline [2]. Patients had received pirfenidone for ⩾16 weeks and tolerated a stable dose of 1602–
2403 mg·day−1 for ⩾28 days without experiencing any moderate or severe adverse reactions considered by
the investigator to be related to pirfenidone, or a pirfenidone treatment interruption for >7 days for any
reason. Patients also had forced vital capacity (FVC) % pred ⩾50% and diffusing capacity of the lung for
carbon monoxide (DLCO) % pred ⩾30% at screening. Informed consent was obtained from each patient
before any study activity or treatment was undertaken. Other inclusion and exclusion criteria are listed in
supplementary table S1.
Study design
This was an international, single-arm, open-label, phase IV study (ClinicalTrials.gov identifier
NCT02598193) that assessed safety and tolerability of 24 weeks of treatment with pirfenidone (1602–
2403 mg·day−1) and nintedanib (200–300 mg·day−1) in patients with IPF (figure 1). Patients started
nintedanib treatment that was added to stable pirfenidone treatment on day 1 of the study. Combination
treatment administration is further described in the supplementary methods .
Medications prohibited during the study are described in supplementary table S2.
Assessments
The primary objective was to investigate safety and tolerability of adding nintedanib to stable pirfenidone
treatment in patients with IPF. This was assessed with the following end-points. 1) Primary end-point:
proportion of patients who completed 24 weeks of combination treatment on pirfenidone (1602–
2403 mg·day−1) and nintedanib (200–300 mg·day−1). 2) Secondary end-points: a) proportion of patients
who discontinued pirfenidone, nintedanib or both treatments before week 24 due to treatment-emergent
AEs (TEAEs; AEs occurring after initiation of combination treatment until 28 days after the last dose of
pirfenidone and nintedanib), b) total patient days of combination treatment, c) total duration in days from
initiation of combination treatment to discontinuation of pirfenidone, nintedanib or both treatments, and
d) frequency and timing of TEAEs and serious TEAEs. Changes from baseline in FVC, DLCO and King’s
https://doi.org/10.1183/13993003.00230-2018 2
INTERSTITIAL LUNG DISEASES | K.R. FLAHERTY ET AL.
Brief Interstitial Lung Disease (K-BILD) questionnaire [22] score were assessed as exploratory end-points.
Further details on study assessments are described in the supplementary methods.
Statistical analysis
This study planned to enrol 80 patients based on the sample size prediction described in the
supplementary methods.
The safety population was defined as the population of all patients enrolled who received at least one dose
of pirfenidone or nintedanib at baseline. Percentages were calculated based on number of patients with
nonmissing data. Confidence intervals were based on a binomial distribution. This was a safety and
tolerability study, with only one treatment group, which was not designed to assess efficacy of combination
treatment. Thus, no formal statistical hypotheses were assessed and analyses were limited to descriptive
statistics with no adjustments for multiplicity of end-points or within-subgroup comparisons.
Results
In total, 89 patients were enrolled from 36 centres in Canada, Denmark, France, Germany, Italy, the
Netherlands, Spain and the USA between January and November 2016. Baseline patient demographics and
TABLE 1 Demographic and baseline characteristics (safety population)
Patients 89
Age years 68.2±6.8
Male 71 (80)
Race
White 84 (94)
Black or African-American 3 (3)
Other# 2 (2)
Weight kg 84.9±15.5
Body mass index kg·m−2 28.6±4.6
Previous tobacco use 61 (69)
Duration of previous pirfenidone treatment months 20.4±12.3
FVC % pred mean±SE
Historical value closest to 6 months prior to screening¶ 72.6±1.7
At baseline 71.8±1.7
Patients categorised by baseline FVC % pred
<65% 32 (36)
65–<80% 31 (35)
⩾80% 26 (29)
DLCO % pred mean±SE
Historical value closest to 6 months prior to screening+ 50.0±1.4
At baseline 48.4±1.3
Data are presented as n, mean±SD or n (%), unless otherwise stated. FVC: forced vital capacity; DLCO:
diffusing capacity of the lung for carbon monoxide. #: includes Asian and mixed Asian/White; ¶: mean±SD
time from assessment of historical value to screening was 3.0±1.9 months (n=87); +: mean±SD time from
assessment of historical value to screening was 3.3±2.6 months (n=87).
Pirfenidone
treatment
Pirfenidone+nintedanib
Study period
Washout#
day –50 to day –22ICF
Add nintedanib
(baseline)
After
28–35
days
Screening
day –21 to day –1
Combination treatment
day 1 to day 168 (week 24) Follow-up visit¶
FIGURE 1 Study design. ICF: informed consent form. #: patients receiving prohibited medication discontinued
that medication during washout (other patients entered directly into screening); ¶: taking place 28–35 days
after the end of combination treatment for patients who completed the 24-week combination treatment
period, or 28–35 days after the decision to discontinue nintedanib for patients who discontinued prematurely
or had treatment interrupted for ⩾28 consecutive days.
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characteristics are shown in table 1. Patients had a mean±SE FVC % pred 71.8±1.7% and DLCO % pred
48.4±1.3% at baseline (table 1). Measurements of FVC and DLCO closest to 6 months before start of
screening were mean±SE 72.6±1.7% and 50.0±1.4% (table 1).
The most commonly reported medical history preferred terms (>10% of patients) were: gastro-oesophageal
reflux disease (49 patients (55%)), hypertension (44 patients (49%)), hyperlipidaemia (20 patients (23%)),
cough (18 patients (20%)), seasonal allergy (17 patients (19%)), IPF (16 patients (18%); entering IPF as
medical history was optional), sleep apnoea syndrome (16 patients (18%)), hypercholesterolaemia
(14 patients (16%)), diabetes mellitus (13 patients (15%)), osteoarthritis (12 patients (14%)), allergic
rhinitis (11 patients (12%)), hypothyroidism (11 patients (12%)), depression (10 patients (11%)), anxiety
(nine patients (10%)), insomnia (nine patients (10%)), benign prostatic hyperplasia (nine patients (10%))
and obesity (nine patients (10%)).
The most commonly reported concomitant medications (>25% of patients) were: proton pump inhibitors
(66 patients (74%)), bronchodilators and antiasthmatics (e.g. salbutamol, ipratropium and budesonide;
52 patients (58%)), statins (41 patients (46%)), vitamins and minerals (41 patients (46%)), steroids
(38 patients (43%)), salicylates (35 patients (39%)), antidiarrhoeals (28 patients (32%)), antihistamines
(26 patients (29%)), herbal, homeopathic and dietary supplements (24 patients (27%)), and nonsteroidal
anti-inflammatory drugs (23 patients (26%)).
73 out of 89 (82%, 95% CI 72.5–89.4%) patients completed 24 weeks of treatment plus follow-up and 69
out of 89 patients (78%, 95% CI 67.4–85.7%) met the primary end-point (completion of 24 weeks of
combination treatment at doses of pirfenidone 1602–2403 mg·day−1 and nintedanib 200–300 mg·day−1)
(figure 2). For the 16 patients who discontinued treatment prematurely, 13 patients discontinued due to
TEAEs, one patient withdrew herself from the study and two patients discontinued for other reasons (one
patient did not want to continue nintedanib and the other was listed for a lung transplant) (figure 2).
The mean±SD daily doses taken during combination treatment were pirfenidone 2339.3±183.7 mg·day−1
and nintedanib 255.4±43.7 mg·day−1 (including nintedanib titration period doses). Although 78 patients
(88%) received the target dose of >1602 mg·day−1 pirfenidone and >200 mg·day−1 nintedanib, 61 patients
(69%) received less than the full dose of pirfenidone (2403 mg·day−1) and/or nintedanib (287 mg·day−1
when including nintedanib titration period doses) overall during the study; the majority of patients did so
Completed 24 weeks of combination treatment
on pirfenidone 1602–2403 mg·day–1 and
nintedanib 200–300 mg·day–1 
(n=69)
Patients enrolled
(n=89)
Patients screened
(n=109)
Treated with combination treatment
(n=89)
Completed 24 weeks of combination treatment# 
plus follow-up
(n=73)
Early discontinuation of combination treatment (n=16)
  TEAE (n=13)
  Withdrawal by patient (n=1)
  Other (n=2)¶
FIGURE 2 Patient disposition. TEAE: treatment-emergent adverse event. #: combined pirfenidone and
nintedanib taken at any dose; ¶: one patient was listed in the active lung transplant list and one patient did not
wish to take nintedanib.
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because of temporary dose reductions and/or interruptions following TEAEs. The total number of patient
days of combination treatment with pirfenidone and nintedanib was 13304 days, excluding dose
interruptions (the expected patient days on treatment being 14952 days). Mean±SD duration of treatment
during the study period was 21.3±6.3, 20.8±6.2 and 21.4±6.3 weeks for pirfenidone, nintedanib and
combination treatment, respectively, excluding dose interruptions. As the exposure analysis considered
treatments administered from the start of combination treatment until study drug completion/early
discontinuation from combination treatment period (as per the electronic case report form), interruptions
of either drug before completion of the combination treatment period caused the mean duration of
individual treatments to be shorter than that recorded for combination treatment.
23 patients (26%) had treatment interruptions: one patient (1%) had one interruption of pirfenidone
alone, 16 patients (18%) had 28 interruptions of nintedanib alone and six patients (7%) had one
interruption each of combination treatment (pirfenidone and nintedanib simultaneously interrupted);
interruptions of combination treatment lasted a mean duration of 4.3 days. Mean length of all pirfenidone
and nintedanib interruptions was 7.6 and 10.3 days, respectively.
88 patients (99%) experienced 670 TEAEs; these were considered to be related to treatment in 74 patients
(83%; 418 treatment-related TEAEs) (table 2). Median (interquartile range) duration of TEAEs was 1.9
(0.3–11.3), 0.4 (0.1–7.1) and 0.5 (0.1–6.4) weeks for TEAEs considered related to pirfenidone, nintedanib,
and both pirfenidone and nintedanib, respectively. 67 patients (75%) experienced gastrointestinal
treatment-related TEAEs; the majority of gastrointestinal events were attributed by investigators to
nintedanib alone (61 patients). Seven patients (8%) experienced treatment-related photosensitivity or rash
TEAEs (table 2).
TABLE 2 Summary of common treatment-emergent adverse events (TEAEs) and TEAEs leading to discontinuation (safety
population#)
Patients with at
least one
TEAE¶
Patients with at least one
TEAE related to
pirfenidone only+
Patients with at least
one TEAE related to
nintedanib only+
Patients with at least one
TEAE related to both
pirfenidone and nintedanib+
TEAEs occurring in ⩾5% of patients
⩾1 TEAE 88 (99)
⩾1 treatment-related TEAE 74 (83) 15 (17) 67 (75) 26 (29)
Diarrhoea 44 (49) 2 (2) 38 (43) 5 (6)
Nausea 41 (46) 3 (3) 31 (35) 12 (14)
Vomiting 21 (24) 1 (1) 16 (18) 7 (8)
Decreased appetite 14 (16) 2 (2) 7 (8) 5 (6)
Fatigue 11 (12) 0 8 (9) 3 (3)
Dyspepsia 8 (9) 1 (1) 6 (7) 1 (1)
Headache 8 (9) 0 7 (8) 1 (1)
Weight decreased 6 (7) 1 (1) 3 (3) 2 (2)
Photosensitivity or rash
TEAEs
7 (8) 4 (5) 2 (2) 1 (1)
Abdominal pain upper 5 (6) 1 (1) 2 (2) 2 (2)
Dizziness 5 (6) 0 4 (5) 1 (1)
TEAEs leading to discontinuation
⩾1 TEAE 13 (15)
⩾1 treatment-related TEAE 11 (12) 0 10 (11) 1 (1)
Nausea 4 (5) 0 3 (3) 1 (1)
Diarrhoea 4 (5) 0 3 (3) 1 (1)
Fatigue 2 (2) 0 2 (2) 0
Weight decreased 2 (2) 0 2 (2) 0
Deep vein thrombosis 1 (1) 0 1 (1) 0
Epigastric discomfort 1 (1) 0 1 (1) 0
Malaise 1 (1) 0 1 (1) 0
Migraine 1 (1) 0 1 (1) 0
Vomiting 1 (1) 0 1 (1) 0
Data are presented as n (%). #: n=89; ¶: each of the patients could have experienced one or more treatment-related TEAE, with the potential for
different events to be related to different treatments; +: assessed by investigators for each therapy using their previous experience with
pirfenidone and/or nintedanib, knowledge of the patient, the circumstances surrounding the event, and an evaluation of any potential
alternative causes.
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13 patients (15%) discontinued treatment due to TEAEs; these TEAEs were attributed to nintedanib alone
in 10 patients (11%), both pirfenidone and nintedanib in one patient (1%), and were considered unrelated
to either treatment in two patients (2%), as assessed by the investigator (table 2). Discontinuation of
combination treatment occurred throughout the trial and there was no clear pattern in the timing of early
discontinuation over the treatment period (figure 3).
18 patients (20%) experienced severe (Common Terminology Criteria for Adverse Events grade ⩾3)
TEAEs; these were considered treatment-related in six patients (7%) (table 3). 16 patients (18%)
experienced 18 serious TEAEs (table 3 and supplementary table S3); two patients (2%) experienced one
serious treatment-related TEAE each, both of which were attributed to nintedanib alone: one patient
experienced a transient ischaemic attack but continued combination treatment without dose modification,
and one patient experienced deep vein thrombosis and discontinued nintedanib but continued pirfenidone
treatment. No fatal TEAEs were reported during the study.
Treatment-related hepatic TEAEs were reported in six patients (7%); these were attributed to nintedanib
alone in five patients (table 3). All events were grade 1 (n=4) or grade 2 (n=1) elevations in liver enzymes,
or grade 1 abnormal hepatic function (n=1).
In an exploratory analysis of efficacy, mean±SE FVC % pred and DLCO % pred declined by 0.8±0.6% and
1.4±0.8%, respectively, from historical values to baseline and by 0.4±0.5% and 1.9±0.8%, respectively, from
baseline to week 24 in patients with available data (supplementary figure S1). An exploratory analysis of
K-BILD from baseline to week 24 found that mean±SD total score decreased by 1.3±8.7, and mean±SD
individual subscores decreased by 2.4±14.3 for the “psychological” domain, 0.7±15.9 for the
“breathlessness and activities” domain, and 3.1±17.0 for the “chest symptoms” domain in patients
completing 24 weeks of combination treatment; these changes might be due to chance, as the standard
deviations are larger than the decreases (supplementary figure S2).
Discussion
This study found that combined treatment with pirfenidone (1602–2403 mg·day−1) and nintedanib (200–
300 mg·day−1) for 24 weeks in 89 patients with IPF was completed by 78% of patients. The safety profile
of combination treatment did not reveal a different pattern of TEAEs to that expected with either
treatment alone. Most TEAEs affected the gastrointestinal system and were mild to moderate in severity.
Furthermore, combination treatment taken for 24 weeks was not associated with increased risk of liver
toxicity or photosensitivity. However, frequency of TEAEs (99%) was high for a 6-month study,
comparable with frequencies observed in the 12-month pirfenidone and nintedanib monotherapy trials
[18, 24]; although common gastrointestinal TEAEs occurred less frequently after 6 months of pirfenidone
or nintedanib monotherapy in these studies [25, 26].
Results of this 24-week study are in line with those of the recent 12-week INJOURNEY trial in terms of
overall TEAE frequency [21]. Both studies found that combination treatment with nintedanib and
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and were therefore censored on the Kaplan–Meier curve (represented by vertical lines).
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pirfenidone had a similar safety profile to that of pirfenidone or nintedanib monotherapy in terms of
proportion of patients experiencing TEAEs and types of TEAEs reported. In the current study, patients
were already tolerating a stable dose of pirfenidone prior to initiation of nintedanib, which may explain
the higher incidence of TEAEs attributed to nintedanib versus pirfenidone by investigators. Similarly, the
INJOURNEY trial (in which patients had already shown tolerability to nintedanib prior to initiating
pirfenidone) found that more patients in the combination therapy group discontinued pirfenidone than
nintedanib, although it should be noted that the study protocol recommended reducing pirfenidone dose
before nintedanib dose for management of AEs other than diarrhoea [21].
In this study, treatment-related diarrhoea (49% of patients) was reported more frequently than any
diarrhoea TEAEs in previous studies of pirfenidone monotherapy (25%) [24] and for combination
treatment in the INJOURNEY trial (38%) [21], but less frequently than any diarrhoea TEAEs in previous
studies of nintedanib monotherapy (62%) [18]. Moreover, treatment-related nausea (46% of patients) was
reported by more patients than any nausea TEAEs in previous studies of pirfenidone or nintedanib
monotherapy (36% and 24%, respectively) [18, 24] and was comparable with nausea TEAEs reported in
the INJOURNEY trial (42%) [21]; however, the durations of the two studies were different, making such
comparisons difficult.
TABLE 3 Summary of severe, serious and hepatic treatment-emergent adverse events (TEAEs)
(safety population#)
Patients
with at
least one
TEAE¶
Patients with at
least one TEAE
related to
pirfenidone only+
Patients with at
least one TEAE
related to
nintedanib only+
Patients with at
least one TEAE
related to both
pirfenidone and
nintedanib+
Severe TEAEs§
⩾1 TEAE 18 (20)
⩾1 treatment-related TEAE 6 (7) 0 5 (6) 1 (1)
Diarrhoea 2 (2) 0 1 (1) 1 (1)
Nausea 2 (2) 0 2 (2) 0
Fatigue 1 (1) 0 1 (1) 0
Muscle spasms 1 (1) 0 1 (1) 0
Weight decreased 1 (1) 0 1 (1) 0
Deep vein thrombosis 1 (1) 0 1 (1) 0
Serious TEAEsƒ
⩾1 TEAE 16 (18)
⩾1 treatment-related TEAE 2 (2) 0 2 (2) 0
Transient ischaemic attack 1 (1) 0 1 (1) 0
Deep vein thrombosis 1 (1) 0 1 (1) 0
Hepatic TEAEs
⩾1 TEAE 7 (8)
⩾1 treatment-related TEAE 6 (7) 0 5 (6) 1 (1)
GGT increased 2 (2) 0 2 (2) 0
ALT increased 2 (2) 0 2 (2) 0
AST increased 1 (1) 0 1 (1) 0
Aminotransferase
increased
1 (1) 0 1 (1) 0
Blood ALP increased 1 (1) 0 1 (1) 0
Hepatic function abnormal 1 (1) 0 1 (1) 0
Elevated liver function test 1 (1) 0 1 (1) 0
Elevated liver enzymes 1 (1) 0 0 1 (1)
Data are presented as n (%). GGT: γ-glutamyltransferase; ALT: alanine aminotransferase; AST: aspartate
aminotransferase; ALP: alkaline phosphatase. #: n=89; ¶: each of the patients could have experienced one
or more treatment-related TEAE, with the potential for different events to be related to different
treatments; +: assessed by investigators for each therapy using their previous experience with pirfenidone
and/or nintedanib, knowledge of the patient, the circumstances surrounding the event, and an evaluation of
any potential alternative causes; §: grade ⩾3 using the AE severity grading scale for the Common
Terminology Criteria for Adverse Events (version 4.03) [23]; ƒ: meet any of the following criteria: are fatal or
life-threatening, require or prolong inpatient hospitalisation, result in persistent or significant disability or
incapacity, are congenital anomalies or birth defects in a neonate or infant born to a mother exposed to
study drug, or are significant medical events in the investigator’s judgement.
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Although the frequency of some TEAEs was higher in this 24-week study than in studies of each therapy
alone, discontinuation rates (18% overall and 15% due to TEAEs) were numerically lower than those over
12 weeks in the INJOURNEY trial and over 52 weeks in the INPULSIS trials, and numerically similar to
those over 52 weeks or more in the ASCEND and CAPACITY trials [9–11, 21]. Real-world data from the
USA suggest that discontinuation rates for pirfenidone and nintedanib are higher in clinical practice (24%
for pirfenidone and 34% for nintedanib; mean follow-up of 8–9 months) than in clinical trials [6, 7, 27].
Therefore, it will be important to further investigate tolerability of combination treatment and develop
strategies to help reduce the burden of gastrointestinal TEAEs. Current strategies to reduce nausea
associated with pirfenidone include taking each dose with food; for reducing diarrhoea or nausea
associated with nintedanib, ensuring adequate hydration and use of antidiarrhoea or antiemetic
medications are recommended [6, 7, 28, 29]. Dose adjustments are also recommended for management of
AEs with both pirfenidone and nintedanib [6, 7], and available data suggest that dose adjustments have a
positive impact on treatment persistence [30] while maintaining the benefit of treatment on FVC decline [31].
In this study, 26% of patients had an interruption of combination treatment, but only 7% had both treatments
simultaneously interrupted (for an average interruption length of ∼4 days). This overall rate is similar to other
clinical trial data for pirfenidone monotherapy (25%) [31].
The exploratory efficacy analyses found that there was little decline in lung function during treatment with
combined pirfenidone and nintedanib, which is similar to results in the INJOURNEY trial [21]. However,
with the absence of a control group and larger sample size, no firm conclusions can be drawn regarding
efficacy of combination treatment in patients with IPF. Quality of life, measured using the K-BILD
questionnaire, did not worsen in patients who completed 24 weeks of treatment, which is in line with
quality of life findings from the EuroQoL-5D questionnaire used in the INJOURNEY trial [21].
The benefits of combining therapies with different mechanisms of action have been demonstrated in a
variety of chronic diseases, including chronic obstructive pulmonary disease, asthma and pulmonary arterial
hypertension (PAH) [32, 33]. Evidence from long-term studies in PAH has demonstrated that combination
treatments targeting endothelin, nitric oxide and/or prostacyclin pathways have the potential to significantly
delay disease progression [33]. Indeed, the treatment strategy for PAH is shifting towards use of first-line
combination therapy [32]. Results of the current study suggest that combination treatment with pirfenidone
and nintedanib could provide a viable future option for patients with IPF. However, combination therapy
might not be suitable for all patients, and further research will be necessary to study long-term benefits and
risks of combination treatment in a controlled study with treatment duration of >6 months.
Limitations of this study include the lack of a control or comparator group and small sample size, which are
due to the exploratory nature of the study. Furthermore, only patients who tolerated pirfenidone were
included, which may introduce a bias towards patients less likely to experience TEAEs, and patients could
have treatment interrupted for <28 consecutive days and still be considered to have completed 24 weeks of
combination treatment. Thus, tolerance to treatment in the real-world might be less than that reflected in
the completion rate. Given that pirfenidone and nintedanib treatment can result in similar AEs [9, 10, 18],
there may have been uncertainty regarding whether some TEAEs were related specifically to pirfenidone or
nintedanib. As nintedanib was added to stable pirfenidone treatment in this study, conclusions cannot be
drawn for pirfenidone added to stable nintedanib treatment or when both treatments are started
simultaneously. Although patients with more advanced IPF (FVC % pred <50% and DLCO % pred <30%)
might also be expected to benefit from combination treatment, these patients were excluded from the trial.
However, eligibility criteria were similar to the pivotal trials [9–11], allowing comparison of safety data
between this study and clinical trials of pirfenidone monotherapy. Finally, changes in FVC, DLCO and
K-BILD were tested as exploratory end-points, and the study was not designed to formally assess efficacy of
combination treatment; historical values were used to compare pre-treatment changes in FVC and DLCO.
Conclusions
Combined use of pirfenidone and nintedanib for 24 weeks was tolerated by the majority of patients with
IPF, and associated with similar types of TEAEs and discontinuation rates expected with either treatment
alone. Results of this trial add to the limited safety data of combination treatment taken for >3 months,
and encourage further study to determine the efficacy and safety of pirfenidone and nintedanib taken as
combination treatment versus monotherapy in patients with IPF.
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